We evaluated whether genetic tests with evidence of clinical and personal utility (i.e. APC and BRCA1/2 tests) are associated with higher satisfaction and a more positive perception of care experience than those with undefined utility (i.e. tests for thrombophilia). A cross-sectional survey was performed through telephone interviews to patients tested for deleterious variants in APC or BRCA1/2 genes, or for inherited thrombophilia (FV Leiden and/or FIIG20210A) during a 5-year period (2008)(2009)(2010)(2011)(2012). Three aspects of patient experience were assessed: effective communication through pre-and post-test genetic counselling; collaboration between caregivers on the management of patient care; and impact of genetic testing on quality of life. Overall 237 patients had telephone interviews. Multivariate logistic regression analyses showed that patients tested for APC or BRCA1/2 variants were more likely to be satisfied with both pre-and post-test counselling than those tested for inherited thrombophilia (APC vs. thrombophilia, p = 0.039 and 0.005; BRCA1/2 vs. thrombophilia, p = 0.030 and <0.001).
Introduction
Over the last decade, researchers and policy makers have made measuring and improving the patient experience of genetic health-care services a high priority [1, 2] . Although focusing on patient experience has been controversial, the bulk of the evidence suggests that high performance in these measures is associated with high performance in other aspects of health-care quality, such as clinical processes, patient adherence to prevention and treatment measures, and even health outcomes, particularly of chronic conditions [3] [4] [5] [6] . Consequently, as for other health-care services, patient satisfaction and perception of their health-care experiences are expected to be increasingly used as a measure of performance in public reporting and programmes related to genetic testing [2, 6] .
Patient evaluation of health-care services is usually based on features such as the interpersonal and communication skills of caregivers, the responsiveness of clinical staff to patient needs, and dialogue between different providers in the clinical process [6] . In the case of predictive genomic applications, such features are complicated by the value-or overall utility-of the genetic information obtained. Overall utility includes the evaluation of clinical measures, such as decreased morbidity and mortality, pursuit of prophylactic treatments or follow-up surveillance, and health-related quality of life [7, 8] , as well as personal or social outcomes that include subjective, non-health-related uses of genetic information such as improving feelings of control, enhancing self-knowledge, and planning for the future [8, 9] . The lack of evidence on personal and/or clinical utility of genetic testing can make it difficult to lead physicians in clinical decision-making and to provide patients with appropriate information, which can therefore have a negative impact on patient experience.
In this study, we evaluated whether genetic tests with evidence of clinical and personal utility are associated with higher satisfaction and a more positive perception of the care experience than genetic tests with undefined utility. As genetic tests with well-defined utility, we included testing for dominant germline variants in the adenomatous polyposis coli (APC) gene, which have almost 100% penetrance and cause about 1% of all colorectal cancers [10] , and testing for dominant variants in one of the breast/ ovarian cancer susceptibility genes (BRCA1, BRCA2), which have 40-70% penetrance and are responsible for 2-7% of breast cancers and 10-15% of ovarian cancers [11] . Genetic testing for two variants (Factor V Leiden and/or FIIG20210A) of inherited thrombophilia, which is associated with low-risk susceptibility to venous thromboembolism (VTE), was selected as a genetic test with undefined utility [12] . Three aspects of patient satisfaction and experience were assessed: effective communication through pre-and post-test genetic counselling; collaboration between health-care providers on the management of patient care; and impact of genetic testing on quality of life.
Methods

Study population
Participants were recruited from the genetic service of the San Camillo-Forlanini Hospital (Rome, Italy). Eligibility criteria were that patients were tested for deleterious variants in APC or BRCA1/2, or for inherited thrombophilia (Factor V Leiden and/or FIIG20210A) during a 5-year period (2008) (2009) (2010) (2011) (2012) , and that they obtained the results of these tests. Patients were excluded if they had prior or ongoing major psychiatric dysfunction or neurological disease. All individuals selected received an advance pack including an informed consent form and a cover letter that outlined the details of the study and informed patients of their guaranteed anonymity. Individuals who agreed to participate completed the informed consent forms and returned them to the genetic service. All telephone interviews were administered by three researchers (ED, EP, MRV) between November 2013 and March 2014. The study was approved by the ethics committee of San Camillo-Forlanini Hospital.
Survey instrument
The set of questions assessed in this study was part of a wider survey designed to investigate the appropriateness of genetic testing delivery and post-testing health-care pathways. The questions evaluate patient socio-demographic and professional characteristics; the familial, clinical, and genetic characteristics of patients (known variant in the family, carrier status, previous primary cancer or thrombotic event, etc.); and the patients' experience of the genetic testing process. Three self-reported elements were used to measure patient experience: patient satisfaction with genetic counselling, patient perception of collaboration between caregivers both within and outside the genetic service, and the impact of genetic testing on patient quality of life.
We posed four questions relating to genetic counselling: two on whether or not pre-and post-test genetic counselling was performed, and two on patient satisfaction with counselling, before and after testing, using a five-point Likert scale ('very satisfied', 'satisfied', 'uncertain', 'dissatisfied', 'very dissatisfied'). Collaboration between health-care actors (as perceived by the patient) was explored through three questions. The first two asked about the kind of physician who referred the patients for testing, and whether the genetic counsellors suggested health-care centres or a specialized team of experts for the management of specific hereditary disorders. The third question investigated patient perception of the collaboration among physicians (specifically clinical geneticists and specialists) through a five-point Likert scale ('definitely yes', 'probably yes', 'uncertain', 'probably no', 'definitely no'). In two final questions, participants were asked whether performing the genetic testing had improved or damaged their quality of life, using a fivepoint Likert scale ('definitely yes', 'probably yes', 'uncertain', 'probably no', 'definitely no').
An extensive pilot phase was conducted with a convenience sample of 30 participants (ten for each type of genetic test) to ensure practicability of the survey, as well as validity and appropriate interpretation of the survey outcomes. On the basis of the comments and suggestions obtained from the pilot study, the questionnaire was revised before distribution to the study sample. Items were only included in the survey instrument if there was consensus on their meaning among participants. A clear need to slim down the questionnaire emerged. Therefore, we decided not to adopt a validated questionnaire and instead to ask about the quality of life, including any damage suffered, using two direct questions. Because the survey was administered by telephone, we attempted to explain the meaning of questions to participants.
Statistical analyses
The demographic and clinical characteristics of the study participants are stratified by type of genetic test. Standard deviations are presented for continuous variables, and relative frequencies for categorical ones. The outcome variables, originally consisting of five categories, were collapsed into two levels. Patients were considered satisfied if they rated their satisfaction as 'very satisfied' or 'satisfied'. Perception of collaboration between providers, selfperceived improvement of quality of life and selfperceived damage to health were considered positive if patients answered 'definitely yes' or 'probably yes'.
Multivariate logistic regression analyses were used to identify the association between the type of genetic testing and (i) patient satisfaction with pre-test and post-test genetic counselling (models 1 and 2); (ii) perceived collaboration between caregivers in the genetic testing pathway (model 3); (iii) perceived improvement in quality of life (model 4). All multivariate models included carrier status as a dichotomous variable (carriers of APC, BRCA1/ 2, Factor V Leiden and/or FIIG20210A variants vs. noncarriers), because carrier status is a potential confounder of associations between type of test and patient experience (satisfaction, perception of adequate collaboration and quality of life). These associations were assessed by the purposeful selection method [13] . Any variable having a significant univariate analysis at p-value (p) <0.25 for an association with the outcome of interest was selected as a candidate for the multivariate analysis. Covariates were removed from the model if they were non-significant at alpha 0.1 and not a confounder, defined as a covariate whose removal caused a change in the main effect of the remaining parameter estimates greater than 20%. Any variables not selected for the original model were added back one at a time, to identify those that make an important contribution in the presence of other variables. After repeating the process of deleting, refitting and verifying, the models contained significant covariates and confounders. Collinear variables were eliminated in the process. In model 1, we detected a quasi-complete separation of the data points of the variable testing type (dummy APC testing). Exact logistic regression was performed to solve this issue [14] . Median unbiased estimates, 95% CI and exact p-value were reported for dummy APC testing in model 1. In model 4, we added interaction terms to investigate if carrier status is an effectmeasure modifier of the association between the tests and self-perceived improvement in quality of life.
STATA version 14.0 was used for all calculations (College Station, Texas, Stata Corporation, 2015). Throughout the paper, p < 0.05 is regarded as significant.
Results
During the study period, 370 eligible patients were approached. Of these, 237 (64%) agreed to participate and completed the questionnaires. Patients tested for APC or BRCA1/2 variants were more likely to complete the survey than those tested for thrombophilia (80% [33/41] 
Sample characteristics
Of the 237 patients who had telephone interviews, 33 (14%) had been tested for APC, 104 (44%) for BRCA1/2 and 100 (42%) for thrombophilia (Factor V Leiden and/or FIIG20210A) variants (Table 1) . On average, patients tested for APC variants were younger than those tested for BRCA1/2 or thrombophilia variants [mean age 36 (±20) years vs. 52 (±14) and 46 (±14), p = 0.203]. The percentage of female respondents ranged from 87% for BRCA1/2 questionnaires to 51% for APC questionnaires (p < 0.01 across groups). Overall, 77% of the sample completed at least high school (45% intermediate and 32% a high level of education), and the level of education was similar across the groups (Table 1 ). More than half of the respondents for the APC (58%) and thrombophilia questionnaires (56%) reported as a carrier of a deleterious variant, while 71% of BRCA1/2 respondents were not carriers (p < 0.01 across groups). Six individuals tested for thrombophilia did not recall having had a genetic test and were not aware of their carrier status. Information about family history and known familial variants varied across the different types of genetic testing (p < 0.01). Sixty-one per cent of patients who underwent APC testing indicated a positive family history and a known deleterious variant in their families. Patients were mainly referred for BRCA testing because of a positive family history, but where the familial variants were unknown (51%). Half of the patients tested for thrombophilia reported no family history and no known variants in their families (Table 1) .
Patient satisfaction with pre-and post-test counselling
Ninety-seven and 98% of all respondents tested for APC and BRCA variants, respectively, received appropriate information before testing, vs. 72% of patients tested for thrombophilia (p < 0.01) ( Table 2) . Of all patients who received pre-testing information, 94% were satisfied with their understanding of the testing procedure, the benefits and limitations of the test, and the possible consequences of the results. Patients tested for APC and BRCA were more satisfied than those tested for thrombophilia (100% and 98% vs. 86%, p = 0.002). Geneticists play a central role in post-test genetic counselling for APC (67%) and BRCA1/2 testing (54%), while the majority of patients tested for thrombophilia received information about test results and their implications from specialists (52%). Few patients interviewed had integrated counselling by both a geneticist and a clinical specialist (Table 2) . Of all patients who had been informed about their results, respondents who received genetic counselling for APC and BRCA1/2 testing were more satisfied than those for thrombophilia testing (p < 0.01).
Patient experience of integrated care management
Specialists played a central role in detecting clinical evidence of potential hereditary diseases and referring patients for related genetic testing (Table 2) . Specifically, gastroenterologists were the specialists that more often referred patients for genetic counselling following APC testing (12 out of 16, 75%), oncologists for genetic counselling following BRCA1/2 testing (57 out of 67, 85%), and gynaecologists for thrombophilia testing (37 out of 94, 39%). Few patients reported being referred for genetic tests by primary care physicians. Overall, very few patients received information, during counselling, about dedicated health-care centres (such as centres for rare diseases) or specialized teams of physicians who are particularly experienced in managing clinical cases like theirs. The majority of patients referred to a lack of communication or collaboration between clinical geneticists and other providers, regardless of the type of test (Table 2 ).
Self-perception by patients of quality of life
Improvements in the quality of life were more likely to be reported by patients who underwent APC and BRCA1/2 testing than by those who underwent thrombophilia tests (p = 0.030). Almost none of the respondents perceived any damage to their lives due to the genetic examinations (Table 2) . Table 3 shows adjusted analyses of patient satisfaction with pre-and post-test genetic counselling (models 1 and 2), perceived collaboration between caregivers in the genetic Patients tested for inherited thrombophilia reported a more positive perception of collaboration between caregivers than those testing for cancer-related hereditary diseases (i.e. APC and BRCA1/2 testing). Among patients with a history of APC and BRCA testing, odds of adequate collaboration were respectively 72 and 51% lower than patients who underwent thrombophilia testing (APC vs. thrombophilia, OR = 0.28, 95% CI 0.08, 1.08; p = 0.064; OR = 0.49, BRCA1/2 vs. thrombophilia, 95% CI 0.17, 1.37; p = 0.174). Moreover, participants who received post-test counselling by both a geneticist and a specialist were more likely to report a positive collaboration between providers compared to those who did not receive counselling (OR = 8.53, 95% CI 2.75, 26.43; p < 0.01). Patients with positive familial history were more likely to report an adequate collaboration between different providers in the genetic pathway (OR = 2.39, 95% CI 1.02, 5.60; p = 0.045).
Multivariate analyses
Findings on the perception of quality of life were more favourable for cancer-related genetic tests than thrombophilia testing (Table 3) . Patients who underwent APC testing were more likely to report an improvement in quality of life than those who underwent thrombophilia testing (OR = 2.97, 95% CI 1.14, 7.72; p = 0.025). We also observed a positive association between patients tested for BRCA1/2 variants, and self-perceived improvement in quality of life (OR = 1.41, 95% CI 0.74, 2.69; p = 0.294). Carrier status was also significantly associated with improvement in quality of life (OR = 0.52, 95% CI 0.28, 0.97; p = 0.040), and this association did not change according to the type of test performed (interaction terms were not significant).
Discussion
The current study explored the relationship between patient experience (as represented by 'satisfaction with genetic counselling', 'perception of collaboration between caregivers' and 'self-perceived change in life quality') and different types of genetic test by interviewing patients who underwent testing at a genetic service. The genetic tests were selected on the basis of their clinical and personal utility. APC and BRCA1/2 tests are strongly predictive with well-defined utility, and their results are widely utilized to lead clinical and personal decision-making [10, 15, 16] . By contrast, no significant clinical and personal benefits result from weakly predictive genetic tests such as that for Factor V Leiden and FIIG20210A [12, 17, 18] . In our study clinical utility was referred to the likelihood that the test results will lead to an improved health outcome, including healthrelated quality of life, pursuit of prophylactic interventions [7, 8] ; while personal utility takes into account the subjective, non-health-related usefulness of the test results (e.g., psychological, social and economic consequences) [8, 9] . Genetic tests with undefined utility can have a negative impact on patient experience and our results partially confirmed this thesis. Our findings showed that the overall satisfaction with genetic counselling was high. Participants tested for thrombophilia were less likely to receive pre-or post-test genetic counselling. In some cases, they were informed only through a written document (Q1, Table 2 ). Furthermore, genetic counselling for thrombophilia tests was mainly performed by clinicians other than geneticists. These results reflect different adopted procedures. Strongly predictive genetic tests for life-threatening diseases-like those resulting from APC or BRCA1/2 variants-were performed together with a genetic counselling service by clinical geneticists. By contrast, Factor V Leiden and FIIG20210A testing can take place either with or without genetic counselling; in both cases, information pre-test and results were communicated in written form.
On average, patients who underwent APC or BRCA1/2 testing were more likely to report a higher degree of satisfaction with pre-and post-test genetic counselling than those tested for thrombophilia. A lower response rate was recorded among patients who underwent thrombophilia testing, which could imply that these patients were on average less sensitive to the topic of the survey, and therefore even less satisfied than what our results reported. One explanation for these results is that thrombophilia tests provide less valuable information than the other two tests. Patients value information such as likelihood of developing a condition due to genetic variants, timing of clinical onset in the life cycle, overall clinical severity and availability of effective interventions that can modify clinical onset and/or disease progression [19, 20] . Inherited thrombophilia is characterized by a low likelihood of developing VTE, which is generally a non-fatal disorder with an unpredictable timing of clinical onset and a lack of effective strategies for prevention [12, 17, 18, 21, 22] . This can be difficult for physicians to communicate effectively, which can cause confusion or distress among recipients, especially if the preventive strategies are limited [19] . A study by Saukko et al. [23] on thrombophilia testing reveals that lessinformed participants did not differ from well-informed ones in terms of adopted preventive measures. More broadly, there is a lack of clear evidence about the clinical and personal utility of thrombophilia testing, which can contribute to patient dissatisfaction with genetic counselling [19, 23] .
We found no clear and meaningful evidence on the association between how patients perceived collaboration between caregivers in the genetic pathway and type of test. The direction of the effect suggested that patients who were tested for inherited thrombophilia were more likely to perceive care integration than those tested for APC or BRCA1/2 variants, although the results were not significant. As expected, participants who received post-test genetic counselling by both a geneticist and a specialist were more likely to report a positive collaboration between providers than those who did not have counselling. International guidelines recommend that genetics services should be integrated with other clinical specialties, or, where there is existing integration, this should be improved [23] . Given that genetics services are undergoing expansion, the overall capacity of clinical geneticists is limited and other professionals need to be trained to support the appropriate change from compartmental services to integrated care management [24, 25] .
It is interesting that none of the 100 interviewed patients was referred for thrombophilia testing by geneticists. More than one-third of the participants were referred by gynaecologists to inform the clinical decision on prescribing a combined oral contraceptive or hormone replacement therapy (HRT), or to support their advice to family members on these issues. This finding is consistent with the current literature [23] , which describes prescription of oral contraceptives or HRT as the main reason for thrombophilia testing. Several studies have reported that most referrals for thrombophilia tests by clinicians were not appropriate and did not follow current guidelines [20, 23] . This contrasts with testing for APC or BRCA1/2 variants, where geneticists have a crucial part to play in the clinical pathway (i.e. patient referral, diagnosis and counselling), even though clinicians guide the care management. The role of primary care physicians in making medical decisions that concern genetic investigations remains very marginal, as confirmed in other studies [26, 27] .
Almost no participants referred to clinical or psychological harms resulting from the genetic information obtained from testing. The direction of our findings on the quality of life showed that patients who underwent APC or BRCA1/2 testing were more likely to indicate improvements in their daily life than those tested for thrombophilia. As reported in other studies, individuals undergoing DNA testing per se (e.g. thrombophilia testing) do not perceive such an experience as exceptional or unusual; indeed, the majority of patients do not even recall having had a genetic test [23, 28] . Consequently, they do not have strong opinions on any consequent improvement in their quality of life. In our study, a large proportion of participants undergoing thrombophilia screening asked interviewers for further clarification of the term 'quality of life', as opposed to patients who were tested for cancer-related diseases (Q8, Table 2 ). Some authors have argued that such requests for further information by patients is because they are being tested for very low-risk genetic susceptibilities, which have little or no impact on their daily activities or health-care management [23, 28] . Thus, answers relating to the quality of life could be indirectly affected by the overall utility of genetic testing for a given condition.
Another finding of our study is that, alongside the type of testing, carrier status can influence the self-perceived quality of life, i.e. non-carriers reported a better quality of life than carriers. This is in line with results obtained by other studies that analysed carrier status as a potential determinant of patient experience outcomes [29] [30] [31] [32] [33] [34] [35] [36] . Carrying a diseasepredisposing variant may cause problems for patients seeking insurance (depending on the health-care context); patients may also experience stigmatization and anxiety for their future health, all of which can be assumed to affect quality of life [29] [30] [31] [32] [33] [34] [35] [36] .
The current study is the first original research to analyse a potential association between patient experience outcomes and type of testing as main predictor, distinguishing between genetic tests with determined or undetermined utility. A qualitative review by Meiser et al. [37] limited the analysis of patient experience to cancer susceptibility testing (i.e. hereditary breast and ovarian cancer, familial adenomatous polyposis, and hereditary non-polyposis colorectal cancer), concluding that the psychological impact of DNA testing is partly a reflection of the clarity of the risk management options associated with the genetic test undertaken. Our research included a genetic susceptibility test, i.e. that for thrombophilia, which provided little or no clarity on risk management, highlighting the issue described by Meiser et al. [37] . Moreover, ours is one of only a few studies that investigate patient outcomes over the mediumto long term. Most of the previous literature is concerned with psychological outcomes over a short period after patients received their test results (a few weeks or months later), while the present study undertook to obtain a better grasp of the perception of quality of life by assessing patient outcomes a mean of 3 years after testing took place.
This study has several limitations, the first concerning the measurement of quality of life. Because a clear need to slim down the questionnaire emerged in the pilot study, we did not administer a validated questionnaire to estimate the quality of life, but instead relied on direct questions. Interviewers explained to patients the meaning of quality of life, including any harms they experienced, using a brief summary based on questions reported in the WHO Quality of Life-BREF [38] . Second, the long time period between testing and interviews could result in recall bias, especially concerning satisfaction with genetic counselling. Another limitation is that, while we controlled for several potential confounders, there could be other factors that are associated with both the outcomes of patient experience and the tests selected for the study (e.g., risk of a cancerous disease, severe changing of lifestyle due to prophylactic surgeries, or misuse of thrombophilia test due to over-prescription). These unmeasured confounders should be taken into account when interpreting the results. A final limitation is the generalizability of the study, in view of the fact that the research was conducted in only one centre. However, the genetic service of San Camillo-Forlanini Hospital provides a reference genetic service and receives a huge number of patient referrals from all over Italy. The study is therefore likely to be representative of the broader Italian population.
Conclusions
Assessment of patient experience helps to define the performance of a genetic service. Our results show that patient experience depends, at least partially, on the type of genetic test carried out, with the overall utility of the test apparently being an important factor. In line with international recommendations, genetic tests should be offered only once their utility has been demonstrated, as in the case of APC and BRCA1/2 testing. Successful models for functional integration of genetics with other clinical specialties can improve patient experience, reducing inappropriate referrals.
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